文献速递药疹与重症皮肤不良反应皮肤肿瘤

BRAF/MEK抑制剂诱发严重皮肤不良反应的系统综述

Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-09-30

该系统综述检索了MEDLINE、EMBASE等数据库,纳入21篇原始文献,共识别31例BRAF/MEKi相关SCAR(23例DRESS,8例SJS/TEN)。维莫非尼几乎为所有病例的致病药物,DRESS多伴肝肾受累,换用达拉非尼可能是安全替代方案。

要点

  • BRAF/MEKi相关SCAR罕见,但维莫非尼需更密切监测。
  • 维莫非尼相关DRESS常于用药15天内出现,伴肝肾受累。
  • 维莫非尼诱发SCAR缓解后,换用达拉非尼可能是安全选择。

核心结论

  • BRAF/MEKi诱导的SCARs总体罕见,维莫非尼是需要更密切监测SCARs的药物。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE、Web of Knowledge和Cochrane Library,无语言限制,最终21篇原始文献纳入定性合成。

主要发现

  • 共识别31例SCAR病例,其中DRESS 23例,SJS/TEN 8例(SJS 1例,TEN 7例)。
  • 除1例为达拉非尼诱导外,其余病例的致病药物均为维莫非尼。
  • SJS/TEN和DRESS从用药到SCAR发作的平均时间分别为15.5天和11.4天。
  • DRESS病例中,肝脏受累占96%,肾脏改变占87%。
  • 既往免疫治疗可能促进SCARs发生。

关键数值与推荐

  • 维莫非尼相关DRESS很可能在治疗最初15天内发生,并伴有肝和肾受累。
  • 维莫非尼诱导的SCAR缓解后,换用达拉非尼似乎是这些患者治疗的安全替代方案。

临床怎么用

  • 对使用维莫非尼的患者,尤其在治疗最初15天内,应密切监测SCARs,并关注肝肾功能。
  • 维莫非尼诱发SCAR缓解后,可考虑换用达拉非尼作为替代治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severe cutaneous adverse reactions (SCARs) [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic syndrome (DRESS), acute generalized exanthematous pustulosis (AGEP), and generalized bullous fixed eruption (GBFE)] are severe drug reactions that often require hospitalization and could be fatal. BRAF and MEK inhibitors (BRAF/MEKi) are a standard of care in patients with BRAF-mutated metastatic melanomas. These agents are administered until disease progression or unacceptable toxicity occurs. This review has focus on BRAF/MEKi-induced SCARs. A systematic search of the following terms: 'vemurafenib', 'cobimetinib', 'dabrafenib', 'trametinib', 'encorafenib', 'binimetinib', 'Acute Generalized Exanthematous Pustulosis', 'Stevens Johnson syndrome', 'Toxic Epidermal Necrolysis', 'Generalized Bullous Fixed Eruption' 'Drug Hypersensitivity Syndrome', and 'DRESS' in simple combination (every drug with each disease) and all in combination, was performed on MEDLINE, EMBASE, Web of Knowledge and The Cochrane Library repositories, with no restriction on language, for original studies. One hundred sixty-eight original articles were found, 26 (retrospective series, case reports and conference abstracts) were selected, and 21 were included in the qualitative synthesis. A total of 31 SCAR cases (23 DRESS and 8 SJS/TEN - 1 SJS and 7 TEN -) were identified. Vemurafenib was the culprit drug in all but one case, which was dabrafenib-induced. Mean time to SCAR onset from drug intake was 15.5 and 11.4 days, for SJS/TEN and DRESS, respectively. For the DRESS cases, hepatic involvement occurred in 96% and renal alterations in 87% of patients. Overall, BRAF/MEKi-induced SCARs are rare. Among them, vemurafenib is the drug that requires more close monitoring for SCARs. Prior immunotherapy can favour SCARs. Vemurafenib DRESS is likely to occur within the first fifteen days of treatment accompanied by hepatic and renal involvement. Following vemurafenib-induced SCAR resolution, switching to dabrafenib seems to be a safe alternative for these patients' treatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Torres-Navarro I, de Unamuno-Bustos B, Botella-Estrada R, et al. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). J Eur Acad Dermatol Venereol. 2020. PMID: 32846030. doi:10.1111/jdv.16894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。